Diet and ovarian cancer prognosis during PARP inhibitor therapy
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how diet affects outcomes in people with ovarian cancer who are taking PARP inhibitors after initial treatment. Participation involves completing a food frequency questionnaire.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to under 75.
- You have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
- You had surgery and platinum-based chemo, and your cancer responded (complete or partial).
- You are now taking a PARP inhibitor as your first maintenance therapy.
- Your medical records have complete treatment details.
- You or your caregiver are able to remember and discuss your diet.
- You do not have severe conditions that require a special diet (like insulin-dependent diabetes, dialysis, or active Crohn's disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a supervised exercise program combined with nutrition counseling can help women with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. It aims to improve quality of life and physical function during treatment.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.